IQAI Stock Overview
IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States.
Notes are coming soon
IQ-AI Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.029|
|52 Week High||UK£0.061|
|52 Week Low||UK£0.015|
|1 Month Change||60.27%|
|3 Month Change||36.05%|
|1 Year Change||-50.21%|
|3 Year Change||-28.66%|
|5 Year Change||-31.18%|
|Change since IPO||-19.31%|
Recent News & Updates
|IQAI||GB Healthcare Services||GB Market|
Return vs Industry: IQAI underperformed the UK Healthcare Services industry which returned -10.7% over the past year.
Return vs Market: IQAI underperformed the UK Market which returned -4.8% over the past year.
|IQAI Average Weekly Movement||11.3%|
|Healthcare Services Industry Average Movement||3.7%|
|Market Average Movement||5.1%|
|10% most volatile stocks in GB Market||11.0%|
|10% least volatile stocks in GB Market||2.7%|
Stable Share Price: IQAI is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: IQAI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States. Its products include IB Clinic, a toolkit of post-processing software plug-ins for integrating into existing medical image visualization applications; IB Rad Tech, a workflow engine that processes customized workflows; IB Neuro, which analyzes MR data sets and generates parametric perfusion maps quantifying changes in contrast over time; and IB Delta Suite that performs a various fundamental radiology operations, including image co-registration, subtraction, class map generation, and export. The company also offers IB DCE, which analyzes conventional T1 weighted images and generates an array of relevant perfusion and permeability parameters; IB Diffusion that analyzes MR diffusion-weighted images and generates apparent diffusion coefficient, extrapolated b-value, IVIM, and other parameter maps; and IB StoneChecker, a medical software tool to aid clinical decision making by providing information about a patient’s kidney stone.
IQ-AI Limited Fundamentals Summary
|IQAI fundamental statistics|
Is IQAI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IQAI income statement (TTM)|
|Cost of Revenue||UK£10.52k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0034|
|Net Profit Margin||-116.04%|
How did IQAI perform over the long term?See historical performance and comparison